Welcome to our dedicated page for Grace Therapeutics SEC filings (Ticker: GRCE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Grace Therapeutics, Inc. (GRCE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Grace Therapeutics is a late-stage biopharma company focused on rare and orphan diseases, and its filings offer detailed information on the development and regulatory status of its lead asset, GTx-104, as well as corporate governance, financing activities, and risk disclosures.
Through current reports on Form 8-K, Grace Therapeutics documents material events such as the submission and FDA acceptance for review of its New Drug Application (NDA) for GTx-104, the establishment of a Prescription Drug User Fee Act (PDUFA) target date, the issuance of a U.S. method-of-use patent titled “Nimodipine Parenteral Administration,” and additional funding obtained via exercises of common stock warrants. These filings also reference press releases that describe the pivotal Phase 3 STRIVE-ON safety trial of GTx-104 in aneurysmal subarachnoid hemorrhage (aSAH) patients.
Investors can review the company’s definitive proxy statement (DEF 14A) for insight into board structure, annual meeting proposals, executive compensation advisory votes, and the appointment of the independent registered public accounting firm. Periodic reports such as the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, when accessed via EDGAR, provide broader context on Grace Therapeutics’ financial condition, risk factors, and development programs, including GTx-102 and GTx-101.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points in lengthy documents, helping users quickly understand the implications of new 8-Ks, 10-Ks, and 10-Qs. Real-time integration with EDGAR means that new filings appear promptly, while Form 4 and related insider transaction reports, when available, can help users track equity activity by directors and officers.
This GRCE filings hub is intended for users who want to analyze how Grace Therapeutics reports its clinical progress, intellectual property developments, financing arrangements, and governance decisions in official SEC documents, with AI-generated overviews to make complex regulatory language more accessible.
Grace Therapeutics, Inc. received an updated ownership report from ADAR1 Capital Management, ADAR1 Capital Management GP, and Daniel Schneeberger on a Schedule 13G/A. The filing shows beneficial ownership of about 9.9% of the common stock, or roughly 1.65 million shares, including common shares and shares underlying prefunded and milestone warrants as of December 31, 2025. Additional warrant shares are excluded because their exercise is limited by a 9.99% beneficial ownership cap. The reporting persons state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Grace Therapeutics, Inc. reported an updated large shareholder position in this amended Schedule 13G. Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, may be deemed to beneficially own 1,586,659 shares of common stock, or 9.99% of the class as of December 31, 2025.
This amount includes 408,456 shares that can be acquired within sixty days through warrant exercises. The reporting persons share voting and dispositive power over these shares, and certify that the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Grace Therapeutics.
Grace Therapeutics reported a net loss of about
Research and development expenses fell to
Grace Therapeutics reported a smaller net loss while advancing its lead drug GTx-104 toward potential approval. For the quarter ended December 31, 2025, net loss was $2.3 million, or $0.14 per share, improving from $4.2 million a year earlier, mainly as research and development spending declined. For the nine months, net loss narrowed to $6.6 million from $10.2 million. Cash and cash equivalents were $18.7 million and total assets $68.5 million, with minimal liabilities of $3.6 million, leaving stockholders’ equity at $64.9 million. The company completed a $13.7 million net private placement in February 2025 and raised an additional $4.0 million from warrant exercises. GTx-104’s New Drug Application was accepted by the FDA with an April 23, 2026 PDUFA date, following a Phase 3 trial that met its primary endpoint and supported an NDA under the 505(b)(2) pathway.
Grace Therapeutics, Inc. received an amended Schedule 13G/A showing that AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman together report beneficial ownership of 907,217 shares of Common Stock, representing 5.9% of the class as of 12/31/2025.
The filing notes an additional 824,742 common shares are issuable upon exercise of warrants that are not currently exercisable because of beneficial ownership limitations. The reporting persons certify the shares were acquired and are held in the ordinary course of business and not to change or influence control of Grace Therapeutics.
Grace Therapeutics, Inc. updated its executive employment arrangements by entering into amendments to existing letter agreements with its CEO and four other executive officers. If an executive is terminated by the company without Cause, and there is no Change in Control, the executive will receive accrued obligations plus continued base salary and COBRA benefits for six months, or twelve months in the case of the CEO. Unvested equity awards are forfeited in this scenario.
If an executive is terminated without Cause or resigns for Good Reason in connection with or within twelve months after a Change in Control, the executive will receive accrued obligations plus a cash payment equal to six months (eighteen months for the CEO) of base salary and target bonus, as well as COBRA premiums for the same period. In this Change in Control context, all unvested equity awards held by the executive will fully vest and become exercisable.
Grace Therapeutics, Inc. director Vimal Kavuru reported a grant of stock options on January 8, 2026. He received a stock option to buy 10,000 shares of Grace Therapeutics common stock at an exercise price of $3.8 per share, held in direct ownership. Following this grant, he beneficially owns options for 10,000 shares.
According to the vesting terms, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, provided he continues to serve the company through each vesting date.
Grace Therapeutics, Inc. director Kottayil George reported a grant of a stock option covering 10,000 shares of common stock of Grace Therapeutics. The option, with an exercise price of $3.8 per share, was awarded on January 8, 2026 and is held directly.
According to the vesting terms, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to George’s continued service on each vesting date.
Grace Therapeutics director Edward Neugeboren received a grant of stock options on January 8, 2026. The award is a stock option (right to buy) covering 10,000 shares of common stock at an exercise price of $3.8 per share, with no cost to receive the option itself.
According to the disclosure, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, as long as Neugeboren continues in service. After this grant, he holds 10,000 derivative securities directly.
Grace Therapeutics director reports stock option grant. Director Brian A. Davis reported receiving a stock option to buy 10,000 shares of Grace Therapeutics, Inc. common stock on January 8, 2026 at an exercise price of $3.8 per share. The filing shows that 25% of the option vests on the grant date, with the remaining 75% vesting in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to his continuous service. Following this grant, he beneficially owned 10,000 derivative securities directly.